PolarityTE — Q1 2021 Earnings Presentation
11 slides from PolarityTE's earnings presentation, May 13, 2021
Slide 1: First Quarter 2021 Financial Results
SkinTE First Quarter 2021 Financial Results = May 13, 2021 = SSS — ©2021 PolarityTE, Inc. All Rights Reserved.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc, (the “Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accurac
Slide 3: Opening Remarks
SkinTE Opening Remarks David Seaburg, Chief Executive Officer © 2021 PolarityTE, Inc. All Rights Reserved,
Slide 4: First Quarter 2021 Revenue Metrics
First Quarter 2021 Revenue Metrics Q1:21 vs Q4:20: + Total Revenue: ~$4.71 million; up 31% QoQ + SkinTE Revenue: ~$1.73 million; up 44% QoQ* + Contract Services Revenue: ~$2.98 million; up 25% up QoQ + Includes $1.69 million from COVID-19 related testing** *These revenues are not expected to recur i
Slide 5: Transition to Clinical Stage Biotech Company with a Proven and Patented Technology
Transition to Clinical Stage Biotech Company with a Proven and Patented Technology Transition to Clinical Stage Biotech Company with: + Data: Positive topline data from a 100 patient diabetic foot ulcer trial and over 1,200 SkinTE applications to date + Demonstrated SkinTE is Commercially Viable: Sk
Slide 6: Regulatory Update
SkinTE Regulatory Update Richard Hague, President & COO — © 2021 PolarityTE, Inc. All Rights Reserved,
Slide 7: Diabetic Foot Ulcer Trial — Topline Results
Diabetic Foot Ulcer Trial — Topline Results Multi-center randomized trial with 100 patients evaluated across 13 sites + 50 patients received SkinTE plus Standard of Care (SOC) + 50 patients received SOC alone Primary Endpoint: 70% (35/50) of patients receiving SkinTE plus SOC had wound closure at 12
Slide 8: Financials
SkinTE Financials Jake Patter. © 2021 PolarityTE, Inc. All Rights Reserved,
Slide 9: Financials
Financials In US$ ‘000 (except per share 4Q 2020 figures) Total Revenues 4,709 3,590 3,337 2,266 Products 1,729 1,202 1,156 944 428 Services 2,980 2,388 2,181 1,322 505 R&D (2,431) (2,297) (2,698) (3,164) (3,373) G&A (6,371) (5,477) (6,264) (5,211) (11,057) S&M (1,526) (1,395) (1,606) (2,024) (3,694
Slide 10: Questions
SkinTE Questions David Seaburg, CEO Richard Hague, President & COO - ~ Jake Patterson, Interim, -CFO- : @ Xpolarityre © 2021 PolarityTE, Inc. All Rights Reserved,
Slide 11: About SkinTE®
About SkinTE® SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deploy